In this series, designed for experienced pharma professionals and executives, Buchanan professionals will tackle critical issues to help you navigate the Pharma Product Lifecycle. In each 30-minute session, we will dive into a specific phase of the lifecycle, provide attendees with the latest pharma updates and cover trends happening within the FDA and the industry in general.
For our second session, Matthew Fedowitz and Barbara Binzak Blumenfeld will discuss:
IP and Exclusivity Considerations for Brand, Generic and 505(b)(2) Manufacturers
Establishing your Patent Portfolio
Extending Product Life Cycles through Evergreening
If you missed the conversation, you can view the recording here.